Over the last 20 years, biological drugs have changed the therapeutic prospect for chronic inflammatory bowel diseases both in the adult and in the child.¹ Infliximab was the first drug that, when its patent expired, had biosimilars authorised by EMA, CT-P13 and SB2 respectively in 2013 and 2016.² The commercialisation of the biosimilars has injected competition in an extremely delicate and expensive sector for the drug industry, with the result that the European Countries have registered a decrease in the official costs of infliximab between 2 and 39%, with peaks over